Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other


Tags
Inv. presentation
Quarterly results

RECURSION PHARMACEUTICALS, INC. (RXRX) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/12/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
10/11/2023 144 Form 144 - Report of proposed sale of securities:
10/10/2023 144 Form 144 - Report of proposed sale of securities:
10/06/2023 4 Gibson Christopher (CEO) has filed a Form 4 on RECURSION PHARMACEUTICALS, INC.
Txns: Sold 59,794 shares @ $7.2085, valued at $431k
Exercised 31,250 options to buy @ $2.48, valued at $77.5k
10/05/2023 4 Borgeson Blake (Director) has filed a Form 4 on RECURSION PHARMACEUTICALS, INC.
Txns: Sold 8,885 shares @ $7.2907, valued at $64.8k
10/04/2023 4 Dar Zavain (Director) has filed a Form 4 on RECURSION PHARMACEUTICALS, INC.
Txns: Granted 1,920 shares @ $0
10/04/2023 4 CHAVEZ R. MARTIN (Director) has filed a Form 4 on RECURSION PHARMACEUTICALS, INC.
Txns: Granted 2,619 shares @ $0
10/04/2023 4 Li Dean Y (Director) has filed a Form 4 on RECURSION PHARMACEUTICALS, INC.
Txns: Granted 1,659 shares @ $0
Gifted 627,705 shares @ $0
10/04/2023 144 Form 144 - Report of proposed sale of securities:
10/03/2023 144 Form 144 - Report of proposed sale of securities:
10/02/2023 4 Larson Tina Marriott (President and COO) has filed a Form 4 on RECURSION PHARMACEUTICALS, INC.
Txns: Sold 3,000 shares @ $7.7198, valued at $23.2k
Exercised 3,000 options to buy @ $1.06, valued at $3.2k
10/02/2023 8-K Quarterly results
09/28/2023 144 Form 144 - Report of proposed sale of securities:
08/24/2023 4 Borgeson Blake (Director) has filed a Form 4 on RECURSION PHARMACEUTICALS, INC.
Txns: Sold 8,885 shares @ $8.9118, valued at $79.2k
08/24/2023 144 Form 144 - Report of proposed sale of securities:
08/22/2023 144 Form 144 - Report of proposed sale of securities:
08/17/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
08/17/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
08/17/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
08/17/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
08/16/2023 144 Form 144 - Report of proposed sale of securities:
08/15/2023 144 Form 144 - Report of proposed sale of securities:
08/15/2023 144 Form 144 - Report of proposed sale of securities:
08/11/2023 4 Gibson Christopher (CEO) has filed a Form 4 on RECURSION PHARMACEUTICALS, INC.
Txns: Converted 10,000 shares @ $0
Gifted 10,000 shares @ $0
Converted 10,000 options to buy @ $0
08/11/2023 8-K/A Submission of Matters to a Vote of Security Holders  Interactive Data
08/10/2023 4 Borgeson Blake (Director) has filed a Form 4 on RECURSION PHARMACEUTICALS, INC.
Txns: Sold 14,498 shares @ $11.0255, valued at $159.8k
Sold 3,272 shares @ $11.7468, valued at $38.4k
08/08/2023 144 Form 144 - Report of proposed sale of securities:
08/08/2023 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
08/08/2023 424B7 Form 424B7 - Prospectus [Rule 424(b)(7)]:
08/08/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/08/2023 8-K Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits  I...
Docs: "Recursion Provides Business Updates and Reports Second Quarter 2023 Financial Results",
"Recursion Bridges the Protein and Chemical Space with Massive Protein-Ligand Interaction Predictions Spanning 36 Billion Compounds",
"Decoding Biology To Radically Improve Lives End of Q2, 2023"
08/04/2023 4 Gibson Christopher (CEO) has filed a Form 4 on RECURSION PHARMACEUTICALS, INC.
Txns: Sold 60,955 shares @ $13.0171, valued at $793.5k
Sold 4,060 shares @ $13.3631, valued at $54.3k
Exercised 8,674 options to buy @ $11.4, valued at $98.9k
Exercised 31,250 options to buy @ $2.48, valued at $77.5k
08/02/2023 144 Form 144 - Report of proposed sale of securities:
07/28/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy